Last reviewed 2026-05-15 · How we verify

High Dose PF-07328948 (high-dose-pf-07328948)

High Dose PF-07328948 is a high-dose treatment developed by Pfizer Inc. for COVID-19. It is a marketed drug with significant revenue of 63.6B. The mechanism of action is not specified. High Dose PF-07328948 has one key indication, COVID-19. It has one clinical trial and no publications. The commercial significance of this drug is substantial due to its revenue. There are no pipeline developments mentioned.

At a glance

Approved indications

• COVID-19

Common side effects

No common side effects on file.

Drug interactions

• Atazanavir
• Cobicistat
• Darunavir
• Fosamprenavir
• Indinavir
• Lopinavir
• Nelfinavir
• Ritonavir
• Saquinavir
• Tipranavir
• Etravirine
• Fosamprenavir/Ritonavir

Key clinical trials

• A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• High Dose PF-07328948 CI brief — competitive landscape report
• High Dose PF-07328948 updates RSS · CI watch RSS
• Pfizer portfolio CI